Who Owns the Trip: Psychedelic Patents and the Enclosure Problem

“Hofmann synthesized LSD in 1943. A psilocybin developer has filed patents on synthetic psilocybin formulations, dosing protocols, and therapy delivery. The enclosure of the psychedelic commons has begun.”

Albert Hofmann synthesized LSD-25 at a Basel drug company. The company held the pharmaceutical patents until they expired. Hofmann consistently argued LSD should be treated as a sacred drug, not a commercial product.

The current psychedelic patent landscape is substantially more aggressive. A psilocybin developer has filed patents not only on its synthetic psilocybin formulation but on manufacturing processes, specific crystal polymorphs, and therapeutic protocols, including the specific combination of drug, therapist training, and environmental conditions constituting the synthetic psilocybin treatment system.

Researchers at Johns Hopkins established a defensive patent program in 2021, filing patents on psychedelic compounds and protocols specifically to ensure prior art was in the public domain, preventing any single entity from monopolizing the space. The Usona Institute committed to non-exclusive licensing.

The indigenous knowledge dimension adds another layer: many compounds under patent consideration were used by indigenous communities for millennia. The ayahuasca patent case (US Patent 5,751,559, cancelled 2003 after indigenous challenge) established that prior art arguments can defeat patents on traditional plant knowledge.

Hofmann's problem child has become a commercial asset. Whether its therapeutic potential will be captured serving patients broadly or primarily shareholders is the central policy question of the current psychedelic industry.

Sources

• Psilocybin developer patent portfolio
• Johns Hopkins Defensive Patent Initiative (2021)
• WIPO IGC (2024)
• Hofmann LSD My Problem Child (1979)